A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

NCT04908683 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

25236

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Viruses
Lower Respiratory Tract Disease

Interventions

BIOLOGICAL: Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF
BIOLOGICAL: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.